Epidermal growth factor binding in the developing male reproductive duct and its regulation by testosterone.
It was shown previously that epidermal growth factor (EGF) plays a role in the testosterone-dependent fetal Wolffian duct differentiation. In this communication, the role of EGF was further investigated by determining whether EGF receptor plays a role in mediating the effect of EGF during Wolffian duct (male duct) differentiation, and experiments were designed to test this hypothesis. EGF-binding activity in cultured cells isolated from the reproductive ducts of 14- to 18-day-old fetal mouse was determined, and the results were evaluated by saturation/Scatchard analysis. Using this analysis, we demonstrate that the fetal mouse Wolffian duct contains EGF-saturable EGF-binding proteins with a binding affinity of 10(-10) M. The binding was temperature, time, and cell concentration dependent. Affinity cross-linking analysis of EGF binding of this tissue indicated the presence of an EGF receptor protein of 150 kilodaltons mol wt. The binding activity increased in parallel with the progression of Wolffian duct differentiation during the 14th to 18th day of gestation, which is the critical period of Wolffian duct differentiation. The binding activity was barely detectable at the onset of differentiation, i.e. on the 14th day of gestation. Binding activity in the male duct was higher than that in the female duct. Prenatal administration of testosterone during days 13-17 of gestation increased the EGF receptor concentration in the masculinized female fetuses, suggesting a role of fetal testicular testosterone in determining EGF-binding activity. Prenatal treatment of cyproterone acetate (an antiandrogen at the level of androgen receptor binding to androgen), however, produced no effect on EGF-binding activity in male fetuses. Thus, a role for the EGF receptor is indicated during Wolffian duct differentiation. Testosterone appears to play a role in modulating EGF-binding activity. Further work is necessary to determine the mechanism by which testosterone modulates EGF-binding activity in this tissue.
Gupta
C
C
Department of Pediatric Endocrinology, Children's Hospital of Pittsburgh, Rangos Research Center, University of Pittsburgh, Pennsylvania 15213.
Jaumotte
J
J
D000726:Androgen Antagonists / Q000494:pharmacology; D000728:Androgens / Q000494:pharmacology; D000818:Animals; D003432:Cross-Linking Reagents; D004815:Epidermal Growth Factor / Q000378:metabolism*; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005333:Fetus / Q000378:metabolism*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D012733:Sex Differentiation; D013739:Testosterone / Q000494:pharmacology*; D014928:Wolffian Ducts / Q000166:cytology / Q000196:embryology / Q000378:metabolism*
D000726:Androgen Antagonists; D000728:Androgens; D003432:Cross-Linking Reagents; D013739:Testosterone; D004815:Epidermal Growth Factor; D066246:ErbB Receptors